Interferons in relapsing-remitting multiple sclerosis

Multiple Sclerosis Therapeutics

Volumn , Issue , 2007, Pages 373-392

  Kappos, Ludwig ^a   Lindberg, Raija L P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149464212     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (104)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond (Biol) 1957; 147: 258-67
2. Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 1994; 51: 1245-52
3. Jacobs L, O'Malley JA, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1982; 214: 1026-8
4. Jacobs L, O'Malley JA, Freeman A, et al. Intrathecal interferon in multiple sclerosis. Arch Neurol 1982; 39: 609-15
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
6. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7
7. Arnason BGW. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996; 81: 1-11
8. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15
9. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001; 14: 361-8
10. Hohlfeld R. Biotechnological agents for the immuno-therapy of multiple sclerosis. Brain 1997; 120: 865-916
11. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-5
12. Leppert D, Waubant E, Bürk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52
13. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997; 41: 669-74
14. Liu Z, Pelfrey CM, Cotleur A, et al. Immuno-modulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 153-62
15. Teleshova N, Kivisakk P, Ozenci V, et al. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment. Scand J Immunol 2000; 51: 312-20
16. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T-cells alive. J Exp Med 1999; 189: 521-30
17. Pilling D, Akbar AN, Girdlestone J, et al. Interferon beta mediates stromal cell rescue of T-cells from apoptosis. Eur J Immunol 1999; 29: 1041-50
18. Borthwick NJ, Lowdell M, Salmon M, Akbar AN. Loss of CD28 expression on CD8(+) T-cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol 2000; 12: 1005-13
19. Kaser A, Nagata S, Tilg H. Interferon alpha augments activation-induced T-cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 1999; 11: 736-43
20. Zipp F, Beyer M, Gelderblom H, et al. No induction of apoptosis by IFN-beta in human antigen-specific T-cells. Neurology 2000; 54: 485-7
21. Lombardi G, Dunne PJ, Scheel-Toellner D, et al. Type I IFN maintains the survival of anergic CD4+ T-cells. J Immunol 2000; 165: 3782-9
22. Rep MHT, Schrijver HM, van Lopik T, et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferongamma producing T-cells in MS patients. J Neuro-immunol 1999; 96: 92-100
23. Perini P, Wadhwa M, Buttarello M, et al. Effect of IFN beta and anti-IFN beta antibodies on NK cells in multiple sclerosis patients. JNeuroimmunol 2000; 105: 91-5
24. Muraro PA, Leist TP, Bielekova B, McFarland H. VLA4/CD49d downregulated on primed T lymphocytes during interferon beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111: 186-94
25. Ozenci V, Kouwenhoven M, Teleshova N, et al. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment of multiple sclerosis. J Neuro-immunol 2000; 108: 236-43
26. Furlan R, Bergami A, Lang R, et al. Interferon beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferongamma and interleukin-4. J Neuroimmunol 2000; 111: 86-92
27. Becher B, Giacomini PS, Pelletier D, et al. Interferongamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999; 45: 247-50
28. Sciacca FL, Canal N, Edoardo Grimaldi LM. Induction of IL-1 receptor antagonist by interferon beta: implication for the treatment of multiple sclerosis. J Neurovirol 2000; 6: 33-7
29. Zang YCQ, Halder JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon beta. J Neuroimmunol 2001; 112: 100-7
30. Iaorlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing- remitting multiple sclerosis patients treated with interferon beta-1b. J Neuroimmunol 2000; 107: 100-7
31. Hua LL, Liu JSH, Brosnan CF, Lee SC. Selective inhibition of human glial inducible nitric oxide synthase by interferon beta: implications for multiple sclerosis. Ann Neurol 1998; 43: 384-7
32. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-27
33. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-300
34. Wandinger KP, Stürzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349-57
35. Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002; 51: 165-74
36. Stürzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419-29
37. Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-B in multiple sclerosis patients. J Immunol 2003; 171: 2694-702
38. Koike F, Satoh J-I, Miyake S, et al. Microarray analysis identifies interferon B-regulated genes in multiple sclerosis. J Immunol 2003; 139: 109-18
39. Hong J, Zang YCQ, Hutton G, et al. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Immunol 2004; 152: 126-39
40. Iglesias AH, Camelo S, Hwang D, et al. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol 2004; 150: 163-77
41. Achiron A, Gurevich M, Friedman N, et al. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004; 55: 410-17
42. Baranzini SE, Mousavi P, Rio J, et al. Transcription-based prediction of response to IFN beta using supervised computational methods. PLoS Biol 2005; 3: 166-76
43. Rani MR, Ransohoff RM. Alternative and accessory pathways in the regulation of IFN-beta-mediated gene expression. J Interferon Cytokine Res 2005; 25: 788-98
44. Hughes R. Wait for further evidence confirming effect of interferon beta in multiple sclerosis. Br Med J 1997; 314: 1763
45. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996; 47: 123-9
46. Myhr KM, Riise T, Green Lilleas FE, et al. Interferon alpha-2a reduces MRI disease activity in relapsing- remitting multiple sclerosis. Neurology 1999; 52: 1049-56
47. Polman CH, Herndon R, Pozzilli C. Interferons. In Rudick RA, Goodkin DE, eds. Multiple Sclerosis Therapeutics. London: Martin Dunitz, 1999: 243-76
48. Leary SM, Stevenson VL, Miller DH, Thompson AJ. Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis. J Neurol 1999; 246: 562-8
49. Rask C, Unger E, Walton M. Comparative study of Rebif to Avonex and orphan exclusivity: comparative memorandum. Rockville, MD: FDA, Division of Clinical Trial Design and Analysis, 2002
50. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis. Neurology 1995; 45: 1277-85
51. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler 1995; 1: 118-35
52. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
53. Simon JH, Jacobs LD, Campion MK, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87
54. Jacobs LD, Beck RW, Simon JH, et al. The effect of intramuscular interferon beta-1a treatment initiated at the time of a first acute clinical demyelinating event on the rate of development of clinically definite multiple sclerosis. N Engl J Med 2000; 343: 898-904
55. The PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1b in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-504
56. Li DKB, Paty DW, the UBC MS/MRI Analysis Research Group and the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197-206
57. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82
58. Comi G, Barkhof F, Durelli L, et al. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Mult Scler 1995; 1 (Suppl 1): S24-S27
59. Freedman M, and the OWIMS Study Group. Evidence of interferon beta-1a dose response in relapsing- remitting MS: the OWIMS Study. Neurology 1999; 53: 679-86
60. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a (Avonex) in relapsing-remitting MS. Neurology 2002; 249: 1088-97
61. The European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
62. Goodkin D, and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54: 2352
63. Li DKB, Zhao GJ, Paty D, and the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS-MRI results. Neurology 2001; 56: 1505-13
64. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS - clinical results. Neurology 2001; 56: 1496-504
65. Cohen JA, Cutter G, Fischer J, Goodman A, et al. Benefit of interferon beta-1a on MSFC progression and quality of life in secondary progressive MS. Neurology 2002; 59: 679-87
66. Coyle P. Results of a comparative efficacy trial using two formulations of interferon beta-1a. J Neurol Sci 2001; 187: S436
67. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60
68. Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66: 1056-60
69. Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001; 7: 349-53
70. Trojano M, Liguori M, Paolicelli D, et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003; 9: 451-7
71. The PRISMS Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001; 56: 1628-36
72. Kappos L, Clanet M, and the European IFN beta-1a (Avonex) Dose-Comparison Study Group. Sustained efficacy of interferon beta-1a in relapsing multiple sclerosis: 4-year results from the European dose-comparison study. Presented at the 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado, April 2002
73. Durelli L, Ferrero B, Oggero A, et al. A multicenter trial comparing clinical and MRI efficacy of interferon beta-1a and beta-1b in multiple sclerosis. J Neurol 2001; 248 (Suppl 2): II/62
74. Kappos L, Polman C, Freedman M, et al. Treatment with interferon beta-1b delays conversion to cloni-cally definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: in press.
75. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-90
76. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-84
77. Walther EU, Hohlfeld R. MS: side-effects of interferon beta-therapy. Neurology 1999; 53: 1623-7
78. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18
79. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94
80. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 273
81. Arnason GB, Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: summary of an international workshop on anti-interferon antibodies. J Interferon Cytokine Res 1998; 18: 639-44
82. Reder AT, Antel JP. Injecting rationale into interferonbeta therapy. Neurology 2000; 54: 2034-5
83. Pachner AR, Dail D, Pak E, Narayan K. The Importance of measuring IFNB bioactivity: monitoring in MS patients and the effect of anti-IFNB antibodies. J Neuroimmunol 2005; 166: 180-8
84. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNb in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Meth 2001; 256: 141-52
85. Pachner A, Narayan K, Price N, et al. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25
86. Gilli F, Marnetto F, Stefanuto G, et al. Comparison of three PCR assays for the evaluation of interferonbeta biological activity in patients with multiple sclerosis. Mol Diagn 2004; 8: 185-94
87. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon B bioavailabil-ity in MS patients. Neurology 2003; 60: 634-9
88. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37-43
89. Ross C, Clemmesen KM, Svensson M, et al. Immuno-genicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency and route of administration. Ann Neurol 2000; 48: 706-12
90. Perini P, Facchinetti A, Bulian P, et al. Interferonbeta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56-61
91. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med 1992; 11: 1825-39
92. D'Vachkova Y, Petkau J, White R. Longitudinal analyses for magnetic resonance imaging outcomes in multiple sclerosis clinical trials. J Biopharm Stat 1997; 7: 501-31
93. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-38
94. Francis GS, Rice GP, Alsop JC; PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55
95. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-7
96. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-9
97. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277-9
98. Ross C, Clemmesen KM, Sorensen PS, et al. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39-46
99. Hartung HP, Munschauer F 3rd, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 2005; 12: 588-601
100. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB). Neurology 1996; 47: 865-6
101. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-27
102. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78
103. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS - a combined analysis of the two trials. Neurology 2004; 63: 1779-87
104. Kappos L, Achtinichts L, Dahlke F, et al. Genomics and proteomics: role in the management of multiple sclerosis. J Neurol 2005; 252(Sup 3): III21-27.